<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">bloodjour</journal-id><journal-title-group><journal-title xml:lang="ru">Гематология и трансфузиология</journal-title><trans-title-group xml:lang="en"><trans-title>Russian journal of hematology and transfusiology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">0234-5730</issn><issn pub-type="epub">2411-3042</issn><publisher><publisher-name>ООО Издательский дом «Практика»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.18821/0234-5730-2017-62-2-101-104</article-id><article-id custom-type="elpub" pub-id-type="custom">bloodjour-70</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>КЛИНИЧЕСКИЕ НАБЛЮДЕНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>CASE REPORTS</subject></subj-group></article-categories><title-group><article-title>СЛУЧАЙ ХРОНИЧЕСКОГО МИЕЛОИДНОГО ЛЕЙКОЗА С РЕДКОЙ ВТОРИЧНОЙ ТРАНСЛОКАЦИЕЙ T(3;7)(Q26;Q21)</article-title><trans-title-group xml:lang="en"><trans-title>THE CASE REPORT OF CHRONIC MYELOID LEUKEMIA WITH RARE SECONDARY TRANSLOCATION T(3;7)(Q26;Q21)</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0306-4272</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Каримов</surname><given-names>Х. Я.</given-names></name><name name-style="western" xml:lang="en"><surname>Karimov</surname><given-names>H. Ya.</given-names></name></name-alternatives><bio xml:lang="ru"/><bio xml:lang="en"/><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2345-100X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ассесорова</surname><given-names>Ю. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Assesorova</surname><given-names>Yu. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>100059, г. Ташкент</p><p>Ассесорова Юлиана Юрьевна, кандидат биол. наук, младший научный сотрудник Отдела молекулярной медицины и клеточных технологий</p></bio><bio xml:lang="en"><p>Tashkent, 100059</p><p>Assesorova Yuliana Yu., MD, PhD, senior researcher of the Department of molecular medicine and cell technology </p></bio><email xlink:type="simple">yuliana-as@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-9642-6847</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Казакбаева</surname><given-names>Х. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Kazakbaeva</surname><given-names>H. M.</given-names></name></name-alternatives><bio xml:lang="ru"/><bio xml:lang="en"/><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>НИИ гематологии и переливания крови Министерства здравоохранения Республики Узбекистан</institution><country>Узбекистан</country></aff><aff xml:lang="en"><institution>Scientific Research Institute of Hematology and Blood Transfusion</institution><country>Uzbekistan</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2017</year></pub-date><pub-date pub-type="epub"><day>12</day><month>03</month><year>2019</year></pub-date><volume>62</volume><issue>2</issue><fpage>101</fpage><lpage>104</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Каримов Х.Я., Ассесорова Ю.Ю., Казакбаева Х.М., 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="ru">Каримов Х.Я., Ассесорова Ю.Ю., Казакбаева Х.М.</copyright-holder><copyright-holder xml:lang="en">Karimov H.Y., Assesorova Y.Y., Kazakbaeva H.M.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.htjournal.ru/jour/article/view/70">https://www.htjournal.ru/jour/article/view/70</self-uri><abstract><p>Появление дополнительных хромосомных аномалий при развитии хронического миелоидного лейкоза (ХМЛ) может указывать на неблагоприятное течение и прогрессирование заболевания. Агрессивное течение гемобластозов миелоидного типа может быть связано с изменением активности вовлеченного в перестройку онкогена EVI1, локализованного на длинном плече хромосомы 3. Прогноз ХМЛ, при котором обнаружены структурные аберрации, затрагивающие место дислокации данного гена, остается крайне неблагоприятным. Представленный случай наблюдения демонстрирует редко встречаемую при Ph-положительном ХМЛ транслокацию t(3;7)(q26;q21) у больной в стадии бластного криза и указывает на возможность выявления с помощью стандартного цитогенетического исследования дополнительных генетических перестроек, которые могут быть связаны с прогрессированием заболевания.</p></abstract><trans-abstract xml:lang="en"><p>Additional chromosome rearrangements in patients with chronic myeloid leukemia (CML) may point to the unfavorable prognosis and the progression of the disease. The aggressive course of the myeloid hematological malignancies may be associated with the change of the activity of EVI1 oncogene located in the long arm of chromosome 3 and involved in the rearrangement. The CML prognosis is very unfavorable, when structural aberrations include position of this gene. The case report shows the rare secondary translocation t(3;7) (q26;q21) in Philadelphia-positive CML patient with blast crisis. The standard cytogenetic research methods could reveal additional chromosome rearrangements associated with disease progression.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>хронический миелоидный лейкоз</kwd><kwd>цитогенетика</kwd><kwd>редкая транслокация</kwd></kwd-group><kwd-group xml:lang="en"><kwd>chronic myeloid leukemia</kwd><kwd>cytogenetic</kwd><kwd>rare translocation</kwd></kwd-group><funding-group><funding-statement xml:lang="ru">Работа выполнена при поддержке Государственного гранта Минздрава Республики Узбекистан (ППИ-10 № АДСС 15.14.2).</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Куцев С.И. Эволюция мониторинга лечения хронического миелоидного лейкоза. Гематология и трансфузиология. 2009; 54(4): 37–44.</mixed-citation><mixed-citation xml:lang="en">Kutsev S.I. Evolution of therapy monitoring of chronic myeloid leukemia. Hematology and Transfusiology. Russian journal (Gematologiya i Transfusiologiya). 2009; 54(4): 37–44. (in Russian)</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Андреева С.В., Дроздова В.Д., Кавардакова Н.В. Феномен эволюции клональных хромосомных аномалий при остром миелоидном лейкозе в детском возрасте. Цитология и генетика. 2010; 3: 41–52.</mixed-citation><mixed-citation xml:lang="en">Andreeva S.V., Drozdova V.D., Kavardakova N.V. Phenomenon of the evolution of clonal chromosome aberrations in childhood acute myeloid leukemia. Cytology and genetic. 2010; 3: 41–52. (на англ. Springer)</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Asif M., Hussain A., Rasool M. A rare case of a three way complex variant positive Philadelphia translocation involving chromosome (9;11;22)(q34;p15;q11) in chronic myeloid leukemia: A case report. Oncol. Lett. 2016; 12(3): 1986–8.</mixed-citation><mixed-citation xml:lang="en">Asif M., Hussain A., Rasool M. A rare case of a three way complex variant positive Philadelphia translocation involving chromosome (9;11;22)(q34;p15;q11) in chronic myeloid leukemia: A case report. Oncol. Lett. 2016; 12(3): 1986–8.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Madrigal I., Carrio A., Go´mez C., Rozman M., Esteve J., Nomdedeu B., et al. Fluorescence in situ hybridization studies using BAC clones of the EVI1 locus in hematological malignancies with 3q rearrangements. Cancer Genet Cytogenet. 2006; 170(2): 115–20.</mixed-citation><mixed-citation xml:lang="en">Madrigal I., Carrio A., Go´mez C., Rozman M., Esteve J., Nomdedeu B., et al. Fluorescence in situ hybridization studies using BAC clones of the EVI1 locus in hematological malignancies with 3q rearrangements. Cancer Genet Cytogenet. 2006; 170(2): 115–20.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Bobadilla D., Enriquez E.L., Alvarez G., Gaytan P., Smith D., Slovak M.L. An interphase fluorescence in situ hybridisation assay for the detection of 3q26.2/EVI1 rearrangements in myeloid malignancies. Br. J. Haematol. 2007; 136(6): 806–13.</mixed-citation><mixed-citation xml:lang="en">Bobadilla D., Enriquez E.L., Alvarez G., Gaytan P., Smith D., Slovak M.L. An interphase fluorescence in situ hybridisation assay for the detection of 3q26.2/EVI1 rearrangements in myeloid malignancies. Br. J. Haematol. 2007; 136(6): 806–13.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Haferlach C., Bacher U., Grossmann V., Schindela S., Zenger M., Kohlmann A., et al. Three novel cytogenetically cryptic EVI1 rearrangements associated with increased EVI1 expression and poor prognosis identified in 27 acute myeloid leukemia cases. Genes Chromosomes Cancer. 2012; 51(12): 1079–85. doi: 10.1002/gcc.21992.</mixed-citation><mixed-citation xml:lang="en">Haferlach C., Bacher U., Grossmann V., Schindela S., Zenger M., Kohlmann A., et al. Three novel cytogenetically cryptic EVI1 rearrangements associated with increased EVI1 expression and poor prognosis identified in 27 acute myeloid leukemia cases. Genes Chromosomes Cancer. 2012; 51(12): 1079–85. doi: 10.1002/gcc.21992.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Poppe B., Dastugue N., Vandesompele J., Cauwelier B., De Smet B., Yigit N., et al. EVI1 is consistently expressed as principal transcript in common and rare recurrent 3q26 rearrangements. Genes Chromosomes Cancer. 2006; 45(4): 349–56.</mixed-citation><mixed-citation xml:lang="en">Poppe B., Dastugue N., Vandesompele J., Cauwelier B., De Smet B., Yigit N., et al. EVI1 is consistently expressed as principal transcript in common and rare recurrent 3q26 rearrangements. Genes Chromosomes Cancer. 2006; 45(4): 349–56.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">De Braekeleer M., Le Bris M.J., De Braekeleer E., Basinko A., Morel F., Douet-Guilbert N. 3q26/EVI1 rearrangements in myeloid hemopathies: a cytogenetic review. Future Oncol. 2015; 11(11): 1675–86. doi: 10.2217/fon.15.64.</mixed-citation><mixed-citation xml:lang="en">De Braekeleer M., Le Bris M.J., De Braekeleer E., Basinko A., Morel F., Douet-Guilbert N. 3q26/EVI1 rearrangements in myeloid hemopathies: a cytogenetic review. Future Oncol. 2015; 11(11): 1675–86. doi: 10.2217/fon.15.64.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Henzan H., Yoshimoto G., Okeda A., Nagasaki Y., Hirano G., Takase K., et al. Myeloid/natural killer cell blast crisis representing an additional translocation, t(3;7)(q26;q21) in Philadelphiapositive chronic myelogenous leukemia. Ann. Hematol. 2004; 83(12): 784–8.</mixed-citation><mixed-citation xml:lang="en">Henzan H., Yoshimoto G., Okeda A., Nagasaki Y., Hirano G., Takase K., et al. Myeloid/natural killer cell blast crisis representing an additional translocation, t(3;7)(q26;q21) in Philadelphiapositive chronic myelogenous leukemia. Ann. Hematol. 2004; 83(12): 784–8.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Storlazzi C.T., Anelli L., Albano F., Zagaria A., Ventura M., Rocchi M., et al. A novel chromosomal translocation t(3;7)(q26;q21) in myeloid leukemia resulting in overexpression of EVI1. Ann. Hematol. 2004; 83(2): 78–83.</mixed-citation><mixed-citation xml:lang="en">Storlazzi C.T., Anelli L., Albano F., Zagaria A., Ventura M., Rocchi M., et al. A novel chromosomal translocation t(3;7)(q26;q21) in myeloid leukemia resulting in overexpression of EVI1. Ann. Hematol. 2004; 83(2): 78–83.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Storlazzi C.Т., Albano F. t(3;7)(q26;q21). Atlas Genet. Cytogenet. Oncol. Haematol. 2006; 10(1): 14–5.</mixed-citation><mixed-citation xml:lang="en">Storlazzi C.Т., Albano F. t(3;7)(q26;q21). Atlas Genet. Cytogenet. Oncol. Haematol. 2006; 10(1): 14–5.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Shaffer L.G., Slovak M.L., Campbell L.J., Karger S., eds. ISCN, 2009. An international system for human cytogenetic nomenclature. Basel; 2009.</mixed-citation><mixed-citation xml:lang="en">Shaffer L.G., Slovak M.L., Campbell L.J., Karger S., eds. ISCN, 2009. An international system for human cytogenetic nomenclature. Basel; 2009.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Tien H.F., Chuang S.M., Wang C.H., Lee F.Y., Chien S.H., Chen Y.C., et al. Chromosomal characteristics of Ph-positive chronic myelogenous leukemia in transformation. A study of 23 Chinese patients in Taiwan. Cancer Genet. Cytogenet. 1989; 39(1): 89–97.</mixed-citation><mixed-citation xml:lang="en">Tien H.F., Chuang S.M., Wang C.H., Lee F.Y., Chien S.H., Chen Y.C., et al. Chromosomal characteristics of Ph-positive chronic myelogenous leukemia in transformation. A study of 23 Chinese patients in Taiwan. Cancer Genet. Cytogenet. 1989; 39(1): 89–97.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
